New combo therapy shows promise for Hard-to-Treat head and neck cancer
NCT ID NCT01468896
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find the best dose and see if the combination can shrink tumors. Twenty-three participants are enrolled in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cetuximab and interleukin-12
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced head and neck cancer that has spread or come back.
- What could go wrong
- This is an early-phase trial with only 23 participants, so results may not apply broadly. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- Leftover immunotherapy may boost chemo: new study investigates timing
- New drug cocktail shows promise for tough head and neck cancers